Clinical trial
Hypothermic Oxygenated Machine PErfusion During Ex-vivo SPLITting in Liver Pediatric Transplantation (HOPE SPLIT): A Multicenter Randomized Controlled Trial
NCT07918183 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Hypothermic Oxygenated Machine PErfusion During Ex-vivo SPLITting in Liver Pediatric Transplantation (HOPE SPLIT): A Multicenter Randomized Controlled Trial
- Lead sponsor
- Hospices Civils de Lyon
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- January 31, 2027
- Completion date
- January 31, 2031
- Enrollment
- 200 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
pediatric liver transplantation
Arms
As registered; 2 arms.
-
HOPE group
Use of HOPE (End-ischemic Hypothermic Oxygenated Machine Perfusion) during ex vivo liver splitting
-
Classic static cold storage group
Standard splitting technique performed during static cold storage
Primary endpoints
Registered primary outcome measures; 1 primary.
-
liver graft-related morbidity
The primary endpoint is cumulative liver graft-related morbidity at 1 year after pediatric transplantation.
The primary outcome measure will be the Comprehensive Complication Index which will be calculated as the total of all individual liver-related complications graded by the Clavien-Dindo score.
Lead sponsor's other trials
Hospices Civils de Lyon, most recent start first.
+1,861 more trials See the organization page